Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
TG Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'TG Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the TG Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of TG Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of TG Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of TG Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the TG Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate TG Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of TG Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the TG Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of TG Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of TG Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of TG Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 TG Therapeutics, Inc. Snapshot 5 TG Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 TG Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 TG Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 TG Therapeutics, Inc. - Pipeline Products Glance 14 TG Therapeutics, Inc. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 TG Therapeutics, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 TG Therapeutics, Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 TG Therapeutics, Inc. - Drug Profiles 18 ublituximab 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ibrutinib + ublituximab + TGR-1202 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 TG-1101 + TGR-1202 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 RP-5264 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 IRAK4 Program 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 TG Therapeutics, Inc. - Pipeline Analysis 25 TG Therapeutics, Inc. - Pipeline Products by Target 25 TG Therapeutics, Inc. - Pipeline Products by Route of Administration 26 TG Therapeutics, Inc. - Pipeline Products by Molecule Type 27 TG Therapeutics, Inc. - Pipeline Products by Mechanism of Action 28 TG Therapeutics, Inc. - Recent Pipeline Updates 29 TG Therapeutics, Inc. - Dormant Projects 38 TG Therapeutics, Inc. - Discontinued Pipeline Products 39 Discontinued Pipeline Product Profiles 39 MP-101 39 AST-915 39 cromolyn sodium 39 propofol 39 teriparatide 39 TG Therapeutics, Inc. - Company Statement 40 TG Therapeutics, Inc. - Locations And Subsidiaries 43 Head Office 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables TG Therapeutics, Inc., Key Information 5 TG Therapeutics, Inc., Key Facts 5 TG Therapeutics, Inc. - Pipeline by Indication, 2014 8 TG Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 TG Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 TG Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 TG Therapeutics, Inc. - Partnered Products in Pipeline, 2014 12 TG Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13 TG Therapeutics, Inc. - Phase III, 2014 14 TG Therapeutics, Inc. - Phase II, 2014 15 TG Therapeutics, Inc. - Phase I, 2014 16 TG Therapeutics, Inc. - Preclinical, 2014 17 TG Therapeutics, Inc. - Pipeline by Target, 2014 25 TG Therapeutics, Inc. - Pipeline by Route of Administration, 2014 26 TG Therapeutics, Inc. - Pipeline by Molecule Type, 2014 27 TG Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 28 TG Therapeutics, Inc. - Recent Pipeline Updates, 2014 29 TG Therapeutics, Inc. - Dormant Developmental Projects,2014 38 TG Therapeutics, Inc. - Discontinued Pipeline Products, 2014 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.